These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 30982468)

  • 41. Risk Factors for Opioid-Use Disorder and Overdose.
    Webster LR
    Anesth Analg; 2017 Nov; 125(5):1741-1748. PubMed ID: 29049118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of harm reduction strategies by individuals with a history of incarceration: A short report using baseline data collected from the STAMINA clinical trial.
    Victor G; Ray B; Watson DP
    J Subst Use Addict Treat; 2024 Jul; 162():209376. PubMed ID: 38641053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths.
    Parmar MK; Strang J; Choo L; Meade AM; Bird SM
    Addiction; 2017 Mar; 112(3):502-515. PubMed ID: 27776382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk.
    Brinkley-Rubinstein L; Cloud D; Drucker E; Zaller N
    Curr HIV/AIDS Rep; 2018 Jun; 15(3):255-258. PubMed ID: 29752698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach.
    Bunting AM; Oser CB; Staton M; Eddens KS; Knudsen H
    Addict Sci Clin Pract; 2018 Dec; 13(1):23. PubMed ID: 30509314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fentanyl and the Evolving Opioid Epidemic: What Strategies Should Policy Makers Consider?
    Barry CL
    Psychiatr Serv; 2018 Jan; 69(1):100-103. PubMed ID: 28967324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 'It's our safe sanctuary': Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario.
    Foreman-Mackey A; Bayoumi AM; Miskovic M; Kolla G; Strike C
    Int J Drug Policy; 2019 Nov; 73():135-140. PubMed ID: 31654936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overdose and substance-related mortality after release from prison in Washington State: 2014-2019.
    O'Connor AW; Sears JM; Fulton-Kehoe D
    Drug Alcohol Depend; 2022 Dec; 241():109655. PubMed ID: 36283246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US.
    Ballreich J; Mansour O; Hu E; Chingcuanco F; Pollack HA; Dowdy DW; Alexander GC
    JAMA Netw Open; 2020 Nov; 3(11):e2023677. PubMed ID: 33146732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between non-fatal opioid overdose and encounters with healthcare and criminal justice systems: Identifying opportunities for intervention.
    Wagner KD; Liu L; Davidson PJ; Cuevas-Mota J; Armenta RF; Garfein RS
    Drug Alcohol Depend; 2015 Aug; 153():215-20. PubMed ID: 26091751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A qualitative study of services accessibility for indigenous persons who use injection drugs across three communities in the United States.
    Anastario M; Leston J; Crisp C; Lee C; Rink E
    J Ethn Subst Abuse; 2023; 22(4):804-826. PubMed ID: 35266863
    [No Abstract]   [Full Text] [Related]  

  • 52. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia.
    Green TC; Grau LE; Blinnikova KN; Torban M; Krupitsky E; Ilyuk R; Kozlov A; Heimer R
    Int J Drug Policy; 2009 May; 20(3):270-6. PubMed ID: 18774283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland.
    Buresh M; Gicquelais RE; Astemborski J; Kirk GD; Mehta SH; Genberg BL
    PLoS One; 2020; 15(3):e0230127. PubMed ID: 32160244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors.
    Binswanger IA; Nowels C; Corsi KF; Glanz J; Long J; Booth RE; Steiner JF
    Addict Sci Clin Pract; 2012; 7(1):3. PubMed ID: 22966409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for heroin use following release from jail or prison in adults in a Central Appalachian state between 2012-2017.
    Smith KE; Archuleta A; Staton M; Winston E
    Am J Drug Alcohol Abuse; 2020; 46(4):485-497. PubMed ID: 33223579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.
    Wheeler E; Jones TS; Gilbert MK; Davidson PJ;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):631-5. PubMed ID: 26086633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting.
    Berk J; Del Pozo B; Rich JD; Lee JD
    J Addict Med; 2022 Jul-Aug 01; 16(4):396-398. PubMed ID: 34954747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
    Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
    Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction.
    Hill LG; Evoy KE; Reveles KR
    J Am Pharm Assoc (2003); 2019; 59(6):779-782. PubMed ID: 31402146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.
    Stone J; Degenhardt L; Grebely J; Larney S; Altice FL; Smyrnov P; Rahimi-Movaghar A; Alavi M; Young AM; Havens JR; Miller WC; Hickman M; Vickerman P
    Lancet Psychiatry; 2021 Apr; 8(4):301-309. PubMed ID: 33640039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.